NicOx Revenue and Competitors
Estimated Revenue & Valuation
- NicOx's estimated annual revenue is currently $15.1M per year.
- NicOx's estimated revenue per employee is $201,000
Employee Data
- NicOx has 75 Employees.
- NicOx grew their employee count by 3% last year.
NicOx's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP and Head Clinical Development | Reveal Email/Phone |
3 | VP finance | Reveal Email/Phone |
4 | General Counsel | Reveal Email/Phone |
5 | Chief Scientific Officer | Reveal Email/Phone |
6 | Director Clinical Operations | Reveal Email/Phone |
7 | Director, Pharmaceutical Development & CMC | Reveal Email/Phone |
8 | Sr. Director, R&D Project Management | Reveal Email/Phone |
9 | EVP and Chief Business Officer | Number two to the CEO | Reveal Email/Phone |
10 | Director Clinical Operations | Reveal Email/Phone |
NicOx Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is NicOx?
Nicox is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world. Our global growth strategy is focused on outstanding international collaborations and on our proprietary programs including those from our nitric oxide-donating research platform. For more information please visit www.nicox.com
keywords:N/A
N/A
Total Funding
75
Number of Employees
$15.1M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
NicOx News
said Michele Garufi, Chief Executive Officer of Nicox. Key UpcomingMilestone. Mont Blanc Phase 3 clinical trial on NCX 470 in glaucoma:...
Nicox (OTCMKTS:NICXF) Upgraded to Buy at Zacks Investment Research. Posted by admin on Apr 19th, 2022. Share on Twitter Share on Facebook Share on...
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the results from its Dolomites...
Other Companies in Valbonne
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $18.6M | 75 | 6% | N/A |
#2 | $53.5M | 286 | 6% | N/A |
#3 | $101.9M | 388 | 28% | N/A |